ReCor Medical v. Medtronic Ireland: Renal Denervation Declaratory Action Dismissed
ReCor Medical sought a declaratory judgement against Medtronic Ireland over its Paradise Renal Denervation System, asserting US8845629B2. After 1,139 days before the Northern District of California, the court dismissed all claims and counterclaims without prejudice — finding neither constitutional standing nor subject matter jurisdiction.
A jurisdictional dead-end for ReCor’s declaratory renal denervation play
ReCor Medical, Inc. filed this declaratory judgement action on 25 May 2022 in the Northern District of California, targeting Medtronic Ireland Manufacturing Unlimited Co. and Medtronic Vascular, Inc. The central dispute concerned US8845629B2 and whether ReCor’s Paradise Renal Denervation System — an ultrasound catheter platform designed to treat hypertension by ablating renal nerves — fell within that patent’s scope. ReCor sought a court declaration to neutralise any infringement threat before Medtronic could launch offensive litigation.
The case closed on 7 July 2025 when the court granted ReCor’s own motion to dismiss Medtronic Ireland’s counterclaims for lack of constitutional standing, while simultaneously dismissing ReCor’s declaratory claims for lack of subject matter jurisdiction. Both dismissals were without prejudice, meaning neither side secured a merits ruling and each retains the right to re-litigate if the jurisdictional prerequisites are later satisfied. Medtronic’s motion for joinder was denied as moot.
The 1,139-day duration — nearly three and a half years — without reaching the merits suggests prolonged procedural skirmishing over threshold jurisdictional questions rather than substantive patent disputes. The public record does not reveal why subject matter jurisdiction was ultimately found lacking, which is notable given that declaratory judgement jurisdiction in patent cases typically requires an actual controversy of sufficient immediacy. Whether Medtronic subsequently asserts US8845629B2 offensively, or ReCor refiles if the controversy ripens, remains unresolved.
Filing to Dismissed without Prejudice in 1139 days
1,139 days — above the median for N.D. Cal. patent cases resolved short of trial
Dismissed without prejudice: what the jurisdictional ruling means for both parties
Dismissed without prejudice on jurisdictional grounds — not the merits
A dismissal without prejudice means the court made no finding on whether US8845629B2 is valid, infringed, or enforceable. The court found ReCor’s declaratory claims lacked subject matter jurisdiction and that Medtronic Ireland’s counterclaims lacked constitutional standing. Both parties remain free to refile if the legal prerequisites — including a sufficiently ripe actual controversy — are later met.
No merits adjudicationReCor leaves without the declaratory certainty it sought
ReCor initiated this action to obtain a court declaration clearing the Paradise Renal Denervation System of any infringement threat. The without-prejudice dismissal denies that outcome entirely. The patent threat from US8845629B2 is neither confirmed nor eliminated. ReCor may need to wait for a more concrete Medtronic enforcement action before a court will accept jurisdiction over a renewed declaratory filing.
Patent risk unresolvedMedtronic’s counterclaims dismissed, but patent rights preserved
Medtronic Ireland’s counterclaims were dismissed for lack of constitutional standing — meaning the court found Medtronic Ireland did not have the legally cognisable injury required to pursue those claims at this stage. Critically, this does not extinguish Medtronic’s patent rights. The without-prejudice nature of the dismissal leaves open the possibility of a future offensive infringement action if standing requirements are satisfied or a different Medtronic entity pursues the claims.
Enforcement avenue remains openRenal denervation IP uncertainty persists for the sector
The absence of any merits ruling means the competitive IP boundary between ultrasound-based renal denervation technologies remains undefined. Companies developing or commercialising renal denervation systems — a market gaining clinical momentum following SPYRAL trial data — cannot rely on this decision as clearance or a validity finding. US8845629B2 remains a live enforcement risk, and the dispute is consistent with intensifying IP competition in the catheter-based hypertension treatment space.
IP boundary still undefinedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ReCor Medical, Inc. | Company | Medical device company — holder of US8845629B2, Paradise Renal Denervation SystemSearch in Eureka ↗ |
| Defendant | Medtronic Ireland Manufacturing Unlimited, Co. | Company | Medtronic Ireland Mfg. Unlimited Co. and Medtronic Vascular, Inc. — global medical device groupSearch in Eureka ↗ |
| Co-Defendant | Medtronic Vascular, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Allison Harms | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ashley M. Fry | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Audra M. Sawyer | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Drew W. Roberts | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jacob Vannette | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Keeley Irene Vega | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew Moore | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael R. Seringhaus | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ramya Vallabhaneni | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Roger J. Chin | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins LLP | Law Firm | Representing ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Turner Boyd LLP | Law Firm | Representing ReCor Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Alexander Samuel Krois | Attorney | Counsel for Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant counsel | Bethany Devi Bengfort | Attorney | Counsel for Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant counsel | Brian Curtis Zhang | Attorney | Counsel for Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant counsel | Jacob S. Zweig | Attorney | Counsel for Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant counsel | Jennifer Seraphine | Attorney | Counsel for Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant counsel | Keeley Irene Vega | Attorney | Counsel for Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant law firm | Salisian Lee LLP | Law Firm | Representing Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant law firm | Turner Boyd LLP | Law Firm | Representing Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Defendant law firm | Turner Boyd Seraphine, LLP | Law Firm | Representing Medtronic Ireland Manufacturing Unlimited, Co.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is procedural rather than substantive — it resolves the case entirely on jurisdictional grounds. Granting ReCor’s motion to dismiss Medtronic Ireland’s counterclaims for lack of constitutional standing suggests the named defendant may not have held the requisite legal interest in US8845629B2 to assert claims. Simultaneously dismissing ReCor’s own declaratory claims for lack of subject matter jurisdiction indicates the court found no live, justiciable controversy of sufficient immediacy under the Declaratory Judgment Act. Neither finding reflects on the patent’s validity or ReCor’s infringement position.
US8845629B2 — Ultrasound-based renal denervation catheter system
US8845629B2 (application number US12/754337) covers technology in the catheter-based renal denervation space — specifically ultrasound-mediated ablation of renal sympathetic nerves as a treatment modality for resistant hypertension. Renal denervation works by disrupting the overactive neural signals between the kidneys and the central nervous system that contribute to elevated blood pressure. This patent sits at the core of a competitive and clinically validated technology domain, with renewed commercial interest following positive outcomes in recent clinical trials.
US8845629B2 is strategically significant because ultrasound-based renal denervation represents a differentiated approach relative to radiofrequency ablation methods. Its continued relevance is underscored by the fact that both ReCor Medical — whose Paradise system uses focused ultrasound — and Medtronic, a dominant medtech incumbent, have been willing to invest years of litigation expenditure around it. For competitors or new entrants in catheter-based hypertension therapies, this patent warrants close monitoring given that no court has yet ruled on its validity or scope.
Should your team run an FTO analysis against US8845629B2?
Any organisation developing, commercialising, or investing in catheter-based renal denervation technology — whether ultrasound, radiofrequency, or adjacent energy modalities — should treat US8845629B2 as a live IP risk. The absence of a merits ruling in this case means there is no judicial precedent clearing competing products. The patent remains enforceable, and the dispute between ReCor and Medtronic signals that enforcement posture in this space is active.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US8845629B2 against your product’s technical specifications, identify prior art that could support a validity challenge, and surface related Medtronic and ReCor filings in the renal denervation space. Running a structured FTO analysis now — before Medtronic refiles or identifies a better-positioned entity to assert the patent — reduces exposure and informs your freedom-to-operate position ahead of product launch or investment decisions.
Run a freedom-to-operate analysis on US8845629B2 to assess your product’s exposure
Run FTO in Eureka →Similar renal denervation and medtech declaratory judgement cases
Cases involving declaratory judgement actions over catheter-based medical device patents in the Northern District of California and comparable federal venues.
What this case signals for the renal denervation IP landscape
Jurisdictional dismissals in declaratory patent actions rarely end the underlying dispute — they often precede more aggressive enforcement moves.
Declaratory judgement strategy carries real jurisdictional risk
ReCor’s attempt to obtain pre-emptive patent clearance failed at the threshold. In patent declaratory actions, courts require a genuine, immediate controversy — a perceived threat alone is insufficient. Medical device companies considering a similar DJ strategy should assess whether Medtronic’s conduct created a sufficiently concrete dispute before filing, or risk spending years in litigation that ends without any merits resolution.
US8845629B2 remains a live risk for the renal denervation market
Neither the validity nor the infringement scope of US8845629B2 was adjudicated. Any competitor or entrant in the ultrasound renal denervation space — including those developing catheter-based ablation platforms — should treat this patent as an active enforcement vector. The without-prejudice dismissal effectively resets the clock and leaves Medtronic free to pursue fresh action.
ReCor v Medtronic — key questions answered
The Northern District of California dismissed all claims without prejudice on 7 July 2025. ReCor’s declaratory judgement claims were dismissed for lack of subject matter jurisdiction, and Medtronic Ireland’s counterclaims were dismissed for lack of constitutional standing. No merits ruling was issued on US8845629B2.
A without-prejudice dismissal means neither party is barred from refiling. No finding was made on patent validity, infringement, or enforceability of US8845629B2. ReCor could refile if a justiciable controversy ripens; Medtronic could separately assert the patent if a proper entity with standing brings claims.
US8845629B2 covers catheter-based ultrasound technology for renal nerve ablation, a treatment approach for resistant hypertension. It is relevant to ReCor’s Paradise Renal Denervation System and sits in a clinically active market. Because no court has ruled on its validity or scope, it remains a live enforcement risk for competitors in the space.
Declaratory judgement actions are typically filed when a party believes it faces a credible infringement threat but has not yet been sued. ReCor likely sought judicial confirmation that its Paradise system does not infringe US8845629B2 before Medtronic could initiate offensive litigation. The court ultimately found the controversy was not sufficiently ripe to support DJ jurisdiction.
Yes. Because the dismissal was without prejudice and no merits ruling was issued, Medtronic retains the right to assert US8845629B2 in a future infringement action. The court’s finding that Medtronic Ireland lacked constitutional standing for its counterclaims suggests a different Medtronic entity may need to be the named plaintiff in any future enforcement action.
PatSnap Eureka searches patents and litigation data to answer instantly.